MiR-204 acts as a potential therapeutic target in acute myeloid leukemia by increasing BIRC6-mediated apoptosis

Zhiguo Wang\textsuperscript{a,1,2}, Hong Luo\textsuperscript{a,3}, Zehui Fang\textsuperscript{4}, Yanling Fan\textsuperscript{2}, Xiaojuan Liu\textsuperscript{2}, Yujing Zhang\textsuperscript{4}, Shuping Rui\textsuperscript{2}, Yafeng Chen\textsuperscript{2}, Luojia Hong\textsuperscript{4}, Jincheng Gao\textsuperscript{4}, Mei Zhang\textsuperscript{1}

\textsuperscript{1}Department of Hematology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shanxi Province; \textsuperscript{2}Department of Bone Marrow Transplantation, Harbin Hematological Cancer Institute, Harbin the First Hospital, Harbin; \textsuperscript{3}Department of Hematology, the First Hospital of Qiqihar; \textsuperscript{4}Department of Endocrinology, the 4th Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, People’s Republic of China.

Running title: The anti-carcinogenic role of microRNA-204 in AML

Address correspondence to: Mei Zhang or Zhiguo Wang, Department of Hematology, the 1st Affiliated Hospital of Xi’an Jiaotong University, 277 Yanta West Road, Xi’an, 710061, Shanxi Province, People’s Republic of China. Tel: +86 029 85323112; Fax: ++86 029 85323112. E-mail: zhangmeimed@yeah.net or wangzhiguo91006@163.com

\textsuperscript{a}Wang ZG and Luo H contributed equally to this work
Disclosure of conflict of interest

None.

Figure S1

Figure S1. Enforcing miR-204 expression inhibited human AML cell viability. (A and B) CCK-8 assay of cell viability in AML5, HL-60, Kasumi-1 or U937 cells transfected with miR-204 mimics (miR-204-m) (20 nM) (A) or miR-204 inhibitor (miR-204-i) (20 nM) (B) for 48 h. **P<0.01 vs. control, n=6. (C) The protein expression of cleaved Caspase-3 was examined by western blotting.